FonarFONR
FONR
About: Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
Employees: 520
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
2% more funds holding
Funds holding: 50 [Q3] → 51 (+1) [Q4]
0.46% more ownership
Funds ownership: 49.16% [Q3] → 49.62% (+0.46%) [Q4]
6% less capital invested
Capital invested by funds: $50.3M [Q3] → $47.1M (-$3.21M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for FONR.
Financial journalist opinion
Negative
Zacks Investment Research
20 hours ago
FONR Stock Declines After Q2 Earnings, Revenue and Net Income Fall
FONAR's second-quarter fiscal 2025 revenues and net income decline. Higher costs and lower scan volumes weigh on results.
Neutral
Newsfile Corp
4 days ago
Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025
MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.
Positive
Seeking Alpha
2 months ago
FONAR: Assets Remain Too Cheap To Pass Up
Despite recent underperformance, FONAR remains a value play with minimal debt, positive profitability, and attractive valuation multiples, particularly a P/B ratio of 0.61. Q1-Fiscal 2025 earnings showed a decline, but FONAR's book value continues to grow, driven by strategic investments in high-field MRI scanners and new locations. Risks include market punishment for near-term growth rates and low trading volume, but downside risk is limited due to strong financials and shareholder-friendly trends.
Neutral
Zacks Investment Research
3 months ago
FONR Stock Gains Despite Q1 Earnings Dip and Rising Expenses
FONAR's fiscal first-quarter earnings reveals a decline in revenues and income, driven by decreased patient fees and rising costs, while MRI scan volume sees modest growth.
Neutral
Newsfile Corp
3 months ago
Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025
Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.
Neutral
Zacks Investment Research
4 months ago
FONR's Stock Down Despite Earnings, Revenues Uptick in Fiscal 2024
Strength in FONAR's HMCA segment's revenues drives its top line in fiscal 2024.
Neutral
Newsfile Corp
4 months ago
Fonar Announces Fiscal 2024 Financial Results
Total MRI scan volume at the HMCA-managed sites increased 11% to 209,327 scans for the fiscal year ending June 30, 2024 as compared to the prior year. Cash and Cash Equivalents increased 10% to $56.3 million at June 30, 2024 versus the previous fiscal year.
Positive
Seeking Alpha
7 months ago
FONAR Corporation: Shares Look Ready To Embark On A Sustained Bullish Run (Technical Analysis)
FONAR Corporation showed encouraging growth trends in revenues and earnings, leading to a 'Buy' rating last year. Recent technical trends suggest a potential long-term change in the stock trend, supported by strong near-term growth rates and a favorable valuation. Forward-looking fundamentals, including the adoption of SwiftMR, indicate potential for continued growth and profitability for FONR shareholders.
Positive
Zacks Investment Research
8 months ago
Zacks Initiates Coverage of FONAR Corporation With Outperform Recommendation
Discover why Zacks rates FONAR Corporation as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore FONR's strategic expansion, financial health and market positioning for growth in the MRI diagnostic services space.
Neutral
Newsfile Corp
9 months ago
Fonar Announces Fiscal 2024 Financial Results for 3rd Quarter and Nine-Month Period
Total MRI scan volume at the HMCA-managed sites increased 11% to 154,790 scans for the nine-month period ended March 31, 2024 as compared to the nine-month period ended March 31, 2023. Net Income increased 25% to $12.5 million for the nine-month period ended March 31, 2024 as compared to the nine-month period ended March 31, 2023.
Charts implemented using Lightweight Charts™